ודי לע רשואו קדבנ ונכותו תואירבה דרשמ י"ע עבקנ הז ןולע טמרופ
NAME OF THE MEDICIAL PRODUCT
Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 50 mg lacosamide. Each film-coated tablet contains 100 mg lacosamide. Each film-coated tablet contains 150 mg lacosamide. Each film-coated tablet contains 200 mg lacosamide.
For a full list of excipients, see section 6.1.
Film-coated tablet 50 mg: Pinkish, oval film-coated tablet debossed with ‘SP' on one side and ‘50' on the other side. 100 mg: Dark yellow, oval film-coated tablet debossed with ‘SP' on one side and ‘100' on the other side. 150 mg: Salmon, oval film-coated tablet debossed with ‘SP' on one side and ‘150' on the other side. 200 mg: Blue, oval film-coated tablet debossed with ‘SP' on one side and ‘200' on the other side.
Vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult patients with epilepsy aged 16 years and older.
Posology and method of administration
Posology Vimpat must be taken twice a day. The recommended starting dose is 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week. Depending on response and tolerability, the maintenance dose can be further increased by 50 mg twice a day every week, to a maximum re co m me nd ed daily dose of 400 mg (200 mg twice a day). Vimpat may be taken with or without food.
In accordance with current clinical practice, if Vimpat has to be discontinued, it is recommended this
be done gradually (e.g. taper the daily dose by 200 mg/week). Special population Renal impairment No dose adjustment is necessary in mildly and moderately renally impaired patients (CLCR >30 ml/min). A ma
ximum dose of 250 mg/day is recommended for patients with severe renal
R 30 ml/min) and in patients with endstage renal disease. For patients requiring
haemodialysis a supplement of up to 50% of the divided daily dose directly after the end of haemodialysis is recommended. Treatment of patients with end-stage renal disease should be made with caution as there is little clinical experience and accumulation of a metabolite (with no known pharmacological activity). In all patients with renal impairment, the dose titration should be performed with caution (see section 5.2).
Hepatic impairment No dose adjustment is needed for patients with mild to moderate hepatic impairment. The dose titration in these patients should be performed with caution considering co-existing renal impairment. The pharmacokinetics of lacosamide has not been evaluated in severely hepatic impaired patients (see section 5.2).
Elderly (over 65 years of age) No dose reduction is necessary in elderly patients. The experience with lacosamide in elderly patients with epilepsy is limited. Age associated decreased renal clearance with an increase in AUC levels should be considered in elderly patients (see ‘Use in patients with renal impairment' above and section 5.2).
Paediatric population Vimpat is not recommended for use in children and adolescents below the age of 16 as there is no data on safety and efficacy in these age groups.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 .
Known second- or third-degree atrioventricular (AV) block.
Special warnings and precautions for use
Dizziness Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine (see section 4.8).
Cardiac Rhythm and Conduction Prolongations in PR interval with lacosamide have been observed in clinical studies. Lacosamide should be used with caution in patients with known conduction problems or severe cardiac disease such as a history of myocardial infarction or heart failure. Caution should especially be exerted when treating elderly patients as they may be at an increased risk of cardiac disorders or when lacosamide is used in combination with products known to be associated with PR prolongation.
Second degree or higher AV block has been reported in post-marketing experience. In the placebo- controlled trials of lacosamide in epilepsy patients, atrial fibrillation or flutter were not reported; however both have been reported in open-label epilepsy trials and in post-marketing experience (see section 4.8).
Patients should be made aware of the symptoms of second-degree or higher AV block (e.g. slow or irregular pulse, feeling of lightheaded and fainting) and of the symptoms of atrial fibrillation and flutter (e.g. palpitations, rapid or irregular pulse, shortness of breath). Patients should be counseled to seek medical advice should any of these symptoms occur.
Suicidal ideation and behaviour Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for lacosamide. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge (see section 4.8).
Interaction with other medicinal products and other forms of interaction
Lacosamide should be used with caution in patients treated with medicinal products known to be associated with PR prolongation (e.g. carbamazepine, lamotrigine, pregabalin) and in patients treated with class I antiarrhythmic drugs. However, subgroup analysis did not identify an increased magnitude of PR prolongation in patients with concomitant administration of carbamazepine or lamotrigine in clinical trials.
data Data generally suggest that lacosamide has a low interaction potential. In vitro
studies indicate that the enzymes CYP1A2, 2B6, and 2C9 are not induced and that CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, and 2E1 are not inhibited by lacosamide at plasma concentrations observed in clinical trials. An in vitro
study indicated that lacosamide is not transported by P-glycoprotein in the intestine. In vitro
data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O- desmethyl metabolite.
data Lacosomide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent. Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given 200 mg b.i.d.) but Cmax of midazolam was slightly increased (30%). Lacosamide did not affect the pharmacokinetics of omeprazole (metabolised by CYP2C19 and 3A4, lacosamide given 300 mg b.i.d.). The CYP2C19 inhibitor omeprazole (40 mg q.d.) did not give rise to a clinically significant change in lacosamide exposure. Thus moderate inhibitors of CYP2C19 are unlikely to affect systemic lacosamide exposure to a clinically relevant extent. Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g. fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead to increased systemic exposure of lacosamide. Such interactions have not been established in vivo
but are possible based on in vitro
Strong enzyme inducers such as rifampicin or St John´s wort (Hypericum perforatum) may moderately reduce the systemic exposure of lacosamide. Therefore, starting or ending treatment with these enzyme inducers should be done with caution.
Antiepileptic drugs In interaction trials lacosamide did not significantly affect the plasma concentrations of carbamazepine and valproic acid. Lacosamide plasma concentrations were not affected by carbamazepine and by valproic acid. A population PK analysis estimated that concomitant treatment with other anti-epileptic drugs known to be enzyme inducers (carbamazepine, phenytoin, phenobarbital, in various doses) decreased the overall systemic exposure of lacosamide by 25%.
Oral contraceptives In an interaction trial there was no clinically relevant interaction between lacosamide and the oral contraceptives ethinylestradiol and levonorgestrel. Progesterone concentrations were not affected when the medicinal products were co-administered.
Others Interaction trials showed that lacosamide had no effect on the pharmacokinetics of digoxin. There was
no clinically relevant interaction between lacosamide and metformin. No data on the interaction of lacosamide with alcohol are available.
Lacosamide h a s a low protein binding of less than 15%. Therefore, clinically relevant interactions with other drugs through competition for protein binding sites are considered unlikely.
Fertility, pregnancy and lactation
Pregnancy Risk related to epilepsy and antiepileptic medicinal products in general For all anti-epileptic drugs, it has been shown that in the offspring of women treated with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3% in the general population. In the treated population, an increase in malformations has been noted with polytherapy, however, the extent to which the treatment and/or the illness is responsible has not been elucidated. Moreover, effective anti-epileptic therapy must not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.
Risk related to lacosamide There are no adequate data from the use of lacosamide in pregnant women. Studies in animals did not indicate any teratogenic effects in rats or rabbits, but embryotoxicity was observed in rats and rabbits at maternal toxic doses (see section 5.3). The potential risk for humans is unknown. Lacosamide should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). If women decide to become pregnant, the use of this product should be carefully re-evaluated.
Breastfeeding It is unknown whether lacosamide is excreted in human breast milk. Animal studies have shown excretion of lacosamide in breast milk. For precautionary measures, breast-feeding should be discontinued during treatment with lacosamide.
No adverse effects on male or female fertility or reproduction were observed in rats at
doses producing plasma exposures (AUC) up to approximately 2 times the pla sma AUC in
humans at the maximum recommended human dose (MRHD) 4.7
Effects on ability to drive and use machines
Vimpat may have minor to moderate influence on the ability to drive and use machines. Vimpat treatment has been associated with dizziness or blurred vision. Accordingly, patients should be advised not to drive a car or to operate other potentially hazardous machinery until they are familiar with the effects of Vimpat on their ability to perform such activities.
Summary of safety profile Based on the analysis of pooled placebo-controlled clinical trials in 1,308 patients with partial-onset seizures, a total of 61.9% of patients randomized to lacosamide and 35.2% of patients randomized to placebo reported at least 1 adverse reaction. The most frequently reported adverse reactions with lacosamide treatment were dizziness, headache, nausea and diplopia. They were usually mild to moderate in intensity. Some were dose-related and could be alleviated by reducing the dose. Incidence and severity of CNS and gastrointestinal (GI) adverse reactions usually decreased over time. Over all controlled studies, the discontinuation rate due to adverse reactions was 12.2% for patients randomized to lacosamide and 1.6% for patients randomized to placebo. The most common adverse reaction resulting in discontinuation of lacosamide therapy was dizziness.
Tabulated list of adverse reactions The table below shows the frequencies of adverse reactions which have been reported in pooled placebo-controlled clinical trials (with an incidence rate 1% in the lacosamide group and which are >1% more than placebo) and post-marketing experience. The frequencies are defined as follows: very
common ( 1/10), common ( 1/100 to <1/10), uncommon ( 1/1,000 to <1/100). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
System organ class
disorders Psychiatric disorders
Euphoric mood(2) Psychotic disorder(2) Suicide attempt (2) Suicidal ideation (2) Hallucination (2)
Coordination abnormal Memory impairment Cognitive disorder Somnolence Tremor Nystagmus Hypoesthesia(1) Dysarthria(1) Disturbance in attention(1)
Ear and labyrinth
Atrioventricular block(2) Bradycardia(2) Atrial Fibrillation (2) Atrial Flutter (2)
Constipation Flatulence Dyspepsia(1) Dry mouth(1)
Liver function test abnormal(2)
Skin and subcutaneous
connective tissue disorders General disorders and
Injury, poisoning and
(1) potentially important adverse drug reactions identified as being reported in pooled clinical trials with an incidence rate not meeting the criteria used above. (2) adverse reactions reported in post marketing experience.
Description of selected adverse reactions The use of lacosamide is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation (e.g. atrioventricular block, syncope, bradycardia) may occur. In clinical trials in epilepsy patients the incidence rate of reported first degree AV Block is uncommon, 0.7%, 0%, 0.5% and 0% for lacosamide 200 mg, 400 mg, 600 mg or placebo, respectively. No second or higher degree AV Block was seen in these studies. However, cases with second and third degree AV Block associated with lacosamide treatment have been reported in post-marketing experience.
In clinical trials, the incidence rate for syncope is uncommon and did not differ between lacosamide treated epilepsy patients (0.1%) and placebo treated epilepsy patients (0.3%). Atrial fibrillation or flutter were not reported in short term clinical trials; however both have been reported in open-label epilepsy trials and in post-marketing experience
Laboratory abnormalities Abnormalities in liver function tests have been observed in controlled trials with lacosamide in adult patients with partial-onset seizures who were taking 1 to 3 concomitant anti-epileptic drugs. Elevations of ALT to 3XULN occurred in 0.7% (7/935) of Vimpat patients and 0% (0/356) of placebo patients.
Multiorgan Hypersensitivity Reactions Multiorgan hypersensitivity reactions have been reported in patients treated with some antiepileptic agents. These reactions are variable in expression but typically present with fever and rash and can be associated with involvement of different organ systems. Potential cases have been reported rarely with lacosamide and if multiorgan hypersensitivity reaction is suspected, lacosamide should be discontinued.
There is limited clinical experience with lacosamide overdose in humans.
Symptoms Clinical symptoms (dizziness and nausea) following doses of 1200 mg/day were mainly related to the central nervous system and the gastrointestinal system and resolved with dose adjustments. The highest reported overdose in the clinical development program for lacosamide was 12 g taken in conjunction with toxic doses of multiple other antiepileptic drugs. The subject was initially comatose and then fully recovered without permanent sequelae.
Management There is no specific antidote for overdose with lacosamide. Treatment of lacosamide overdose should include general supportive measures and may include haemodialysis if necessary (see section 5.2).
Pharmacotherapeutic group: other antiepileptics, ATC code: N03AX18 The active substance, lacosamide (R-2-acetamido-N-benzyl-3-methoxypropionamide) is a functionalised amino acid.
Mechanism of action The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated. In vitro
electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes.
Pharmacodynamic effects Lacosamide protected against seizures in a broad range of animal models of partial and primary generalized seizures and delayed kindling development. In non-clinical experiments lacosamide in combination with levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, topiramate or gabapentin showed synergistic or additive anticonvulsant effects.
Clinical efficacy and safety The efficacy of Vimpat as adjunctive therapy at recommended doses (200 mg/day, 400 mg/day) was established in 3 multicenter, randomized, placebo-controlled clinical trials with a 12-week maintenance period. Vimpat 600 mg/day was also shown to be effective in controlled adjunctive therapy trials, although the efficacy was similar to 400 mg/day and patients were less likely to tolerate
this dose because of CNS- and gastrointestinal-related adverse reactions. Thus, the 600 mg/day dose is not recommended. The maximum recommended dose is 400 mg/day. These trials, involving 1308 patients with a history of an average of 23 years of partial-onset seizures, were designed to evaluate the efficacy and safety of lacosamide when administered concomitantly with 1-3 antiepileptic drugs in
patients with uncontrolled partial-onset seizures with or without secondary generalisation. Overall the proportion of subjects with a 50% reduction in seizure frequency was 23%, 34%, and 40% for placebo, lacosamide 200 mg/day and lacosamide 400 mg/day. There are insufficient data regarding the withdrawal of concomitant antiepileptic medicinal products to achieve monotherapy with lacosamide.
Absorption Lacosamide is rapidly and completely absorbed after oral administration. The oral bioavailability of lacosamide tablets is approximately 100%. Following oral administration, the plasma concentration of unchanged lacosamide increases rapidly and reaches Cmax about 0.5 to 4 hours post-dose. Vimpat tablets and oral syrup are bioequivalent. Food does not affect the rate and extent of absorption.
Distribution The volume of distribution is approximately 0.6 L/kg. Lacosamide is less than 15% bound to plasma proteins.
Biotransformation 95% of the dose is excreted in the urine as drug and metabolites. The metabolism of lacosamide has not been completely characterised. The major compounds excreted in urine are unchanged lacosamide (approximately 40% of the dose) and its O-desmethyl metabolite less than 30%. A polar fraction proposed to be serine derivatives accounted for approximately 20% in urine, but was detected only in small amounts (0-2%) in human plasma of some subjects. Small amounts (0.5-2%) of additional metabolites were found in the urine. In vitro
data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed in vivo
. No clinically relevant difference in lacosamide exposure was observed comparing its pharmacokinetics in extensive metabolisers (EMs, with a functional CYP2C19) and poor metabolisers (PMs, lacking a functional CYP2C19). Furthermore an interaction trial with omeprazole (CYP2C19-inhibitor) demonstrated no clinically relevant changes in lacosamide plasma concentrations indicating that the importance of this pathway is minor. The plasma concentration of O-desmethyl-lacosamide is approximately 15% of the concentration of lacosamide in plasma. This major metabolite has no known pharmacological activity.
Elimination Lacosamide is primarily eliminated from the systemic circulation by renal excretion and biotransformation. After oral and intravenous administration of radiolabeled lacosamide, approximately 95% of radioactivity administered was recovered in the urine and less than 0.5% in the feces. The elimination half-life of the unchanged drug is approximately 13 hours. The pharmacokinetics is dose-proportional and constant over time, with low intra- and inter-subject variability. Following twice daily dosing, steady state plasma concentrations are achieved after a 3 day period. The plasma concentration increases with an accumulation factor of approximately 2.
Pharmacokinetics in special patient groups
Gender Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of lacosamide.
Renal impairment The AUC of lacosamide was increased by approximately 30% in mildly and moderately and 60% in severely renal impaired patients and patients with endstage renal disease requiring hemodialysis
compared to healthy subjects, whereas cmax was unaffected. Lacosamide is effectively removed from plasma by haemodialysis. Following a 4-hour haemodialysis treatment, AUC of lacosamide is reduced by approximately 50%. Therefore dosage supplementation following haemodialysis is recommended (see section 4.2). The exposure of the O-desmethyl metabolite was several-fold increased in patients with moderate and severe renal impairment. In absence of haemodialysis in patients with endstage renal disease, the levels were increased and continuously rising during the 24-hour sampling. It is unknown whether the increased metabolite exposure in endstage renal disease subjects could give rise to adverse effects but no pharmacological activity of the metabolite has
Hepatic impairment Subjects with moderate hepatic impairment (Child-Pugh B) showed higher plasma concentrations of lacosamide (approximately 50% higher AUCnorm). The higher exposure was partly due to a reduced renal function in the studied subjects. The decrease in non-renal clearance in the patients of the study was estimated to give a 20% increase in the AUC of lacosamide. The pharmacokinetics of lacosamide has not been evaluated in severe hepatic impairment (see section 4.2).
Elderly (over 65 years of age) In a study in elderly men and women including 4 patients >75 years of age, AUC was about 30 and 50% increased compared to young men, respectively. This is partly related to lower body weight. The body weight normalized difference is 26 and 23%, respectively. An increased variability in exposure was also observed. The renal clearance of lacosamide was only slightly reduced in elderly subjects in this study. A general dose reduction is not considered to be necessary unless indicated due to reduced renal function (see section 4.2).
Preclinical safety data
In the toxicity studies, the plasma concentrations of lacosamide obtained were similar or only marginally higher than those observed in patients, which leaves low or non-existing margins to human exposure A safety pharmacology study with intravenous administration of lacosamide in anesthetized dogs showed transient increases in PR interval and QRS complex duration and decreases in blood pressure most likely due to a cardiodepressant action. These transient changes started in the same concentration range as after maximum recommended clinical dosing. In anesthetized dogs and Cynomolgus monkeys, at intravenous doses of 15-60 mg/kg, slowing of atrial and ventricular conductivity, atrioventricular block and atrioventricular dissociation were seen. In the repeated dose toxicity studies, mild reversible liver changes were observed in rats starting at about 3 times the clinical exposure. These changes included an increased organ weight, hypertrophy of hepatocytes, increases in serum concentrations of liver enzymes and increases in total cholesterol and triglycerides. Apart from the hypertrophy of hepatocytes, no other histopathologic changes were observed. In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but an increase in numbers of stillborn pups and pup deaths in the peripartum period, and slightly reduced live litter sizes and pup body weights were observed at maternal toxic doses in rats corresponding to systemic exposure levels similar to the expected clinical exposure. Since higher exposure levels could not be tested in animals due to maternal toxicity, data are insufficient to fully characterise the embryofetotoxic and teratogenic potential of lacosamide. Studies in rats revealed that lacosamide and/or its metabolites readily crossed the placental barrier.
Environmental Rsik Assessment (ERA) The use of Vimpat in accordance with the product information is unlikely to result in an unacceptable environmental impact.
List of excipients
microcrystalline cellulose hydroxypropylcellulose hydroxypropylcellulose (low substituted) silica, colloidal, anhydrous crospovidone magnesium stearate
Tablet coat: polyvinyl alcohol polyethylene glycol 3350 talc
50 mg tablet: red iron oxide, black iron oxide, indigo carmine aluminium lake 100 mg tablet: yellow iron oxide 150 mg tablet: yellow iron oxide, red iron oxide, black iron oxide 200 mg tablet: indigo carmine aluminium lake
Special precautions for storage
Store below 30°C
Nature and contents of container
PVC/PVDC blister sealed with an aluminium foil. Packs of 14, 56 or 168 film-coated tablets. Not all pack sizes may be marketed.
Special precautions for disposal
No special requirements.
UCB Pharma SA Allée de la Recherche 60 B-1070 Bruxelles Belgium
LICENSE HOLDER AND IMPORTER
CTS LTD 4 Haharash st., Hod hasharon 45240 The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in January 2013
This is a special issue for the International Conferences held by the Australian Society for Commerce Industry and Engineering (SCIE) in Phuket during the 7-8 December 2014. SCIE acknowledges the efforts supported by all authors. The world is improved by your excellent research works. Table of Content A Pilot-scale Study to Reduce Water Consumption in Cotton Dyeing Using Ozone- a Green Approach
A Guide toMalariaManagementProgrammesin the oil and gas industry A Guide toMalaria ManagementProgrammesin the oil and gas industry IPIECAInternational Petroleum Industry Environmental Conservation Association 5th Floor, 209–215 Blackfriars Road, London SE1 8NL, United Kingdom